A blast crisis is the most advanced and dangerous phase of chronic myeloid leukemia (CML), where immature blood cells called blasts multiply rapidly and crowd out healthy blood cells. It transforms what is normally a slow-growing, manageable cancer into something that behaves more like aggressive acute leukemia. The diagnosis is made when blasts make up 20% or more of cells in the blood or bone marrow (by WHO criteria), though some expert panels use a higher threshold of 30%.
How CML Progresses to Blast Crisis
CML typically moves through three phases. The first is the chronic phase, where the disease grows slowly and most people feel relatively well with treatment. Some patients then enter an accelerated phase, where the leukemia becomes harder to control. Blast crisis is the final phase, and it can develop gradually through the accelerated phase or, in some cases, appear suddenly from the chronic phase without much warning.
In the chronic phase, CML is driven by a single genetic abnormality: an abnormal protein that tells white blood cells to keep dividing. Over time, the cancer cells accumulate additional genetic damage that pushes them toward blast crisis. The most common changes involve mutations in the gene that produces that driving protein, making the cancer cells more aggressive and harder to treat. Other critical changes include the loss of p53, a gene that normally forces damaged cells to self-destruct. When p53 stops working, defective cells survive and multiply unchecked. Mutations in genes that control how blood cells mature (like RUNX1) can also block normal development entirely, trapping cells in their immature blast form.
Myeloid vs. Lymphoid Blast Crisis
Not all blast crises look the same under a microscope. About 70% of cases are myeloid blast crisis, where the immature cells resemble the precursors of white blood cells called granulocytes and monocytes. The remaining 30% are lymphoid blast crisis, where the blasts look like immature lymphocytes, almost always of the B-cell type.
This distinction matters because lymphoid blast crisis generally responds better to treatment and is associated with longer survival compared to the myeloid type. Lymphoid blast crisis cells also tend to carry fewer additional chromosomal abnormalities, though they commonly show loss of part of chromosome 9 and deletions in a gene called IKZF1 (found in over half of lymphoid blast crisis patients). The two types are treated differently as well: lymphoid blast crisis is often managed with regimens similar to those used for a related cancer called Philadelphia chromosome-positive acute lymphoblastic leukemia.
Symptoms of Blast Crisis
Many symptoms of blast crisis are intensified versions of what patients experienced in earlier phases of CML, but new and more severe problems emerge as blast cells take over the bone marrow and spill into the bloodstream. The flood of immature cells crowds out the three main types of healthy blood cells, and the consequences follow directly from those shortages.
Low red blood cell counts cause fatigue and weakness. A drop in functional platelets leads to easy bruising and abnormal bleeding. And because the blast cells cannot fight infections the way mature white blood cells do, patients become vulnerable to repeated and sometimes severe infections. Fever is common, and it can signal either the disease itself or an underlying infection. Some people develop worsening bone pain, swollen lymph nodes, or increasing abdominal bloating and discomfort from an enlarging spleen. If blast cells enter the fluid surrounding the brain and spinal cord, headaches can develop.
Why Blast Crisis Is an Emergency
Blast crisis is considered an oncologic emergency. When the white blood cell count climbs extremely high (above 100,000 cells per microliter), a condition called hyperleukocytosis develops. At that level, the sheer volume of abnormal cells can thicken the blood and form plugs in small blood vessels, a complication called leukostasis. Leukostasis most commonly affects the lungs and brain, causing respiratory distress, confusion, vision changes, or stroke-like symptoms.
Other acute complications include tumor lysis syndrome, where the rapid breakdown of cancer cells floods the body with waste products that can damage the kidneys, and disseminated intravascular coagulation, a dangerous disruption of the blood’s clotting system. The most common cause of death in blast crisis is infection resulting from the lack of functional immune cells, followed by hemorrhage from critically low platelet counts.
Treatment Options
The goal of treatment in blast crisis is to reduce the blast count, ideally pushing the disease back into the chronic phase so that longer-term options become possible. Targeted drugs called tyrosine kinase inhibitors (TKIs) are the backbone of CML treatment across all phases. Several TKIs have demonstrated activity against both myeloid and lymphoid blast crisis. For patients whose cancer carries a specific mutation called T315I, which makes most TKIs ineffective, a drug called ponatinib can be used, though outcomes in blast crisis with this drug remain poor.
Patients with lymphoid blast crisis often receive intensive chemotherapy combinations similar to those used for acute lymphoblastic leukemia, paired with a TKI. For myeloid blast crisis, TKIs may be combined with chemotherapy regimens designed for acute myeloid leukemia.
When treatment successfully reduces the disease burden, a stem cell transplant from a matched donor is the only approach with the potential for long-term remission. Transplant is considered whenever feasible, but eligibility depends on factors like age, overall health, and how well the leukemia responded to initial treatment. The reality is that blast crisis carries a significantly worse prognosis than chronic-phase CML, and not all patients are able to achieve a deep enough response to proceed to transplant.
Monitoring to Catch Progression Early
For people living with CML in the chronic phase, regular blood monitoring is essential for catching any signs of progression before a full blast crisis develops. The standard approach uses a highly sensitive lab test called RT-qPCR, which measures the level of the BCR-ABL gene product in the blood. This number serves as a surrogate for how much disease is present: rising levels can signal that treatment is losing effectiveness and the cancer may be advancing.
A newer technique called digital PCR offers even greater accuracy, particularly at very low disease levels. An older test called FISH is less sensitive and generally not recommended for routine follow-up when molecular testing is available. The key takeaway for patients is that consistent monitoring on schedule, typically every three months during treatment, gives the best chance of detecting trouble early, when a change in therapy might prevent progression to blast crisis entirely.